06 September 2022: Original Paper
Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant Recipients
Anna Popova 123ACDE* , Aiga Vasiļvolfa 134ABCDEF , Kārlis Rācenis 12ACD , Renārs Erts 5C , Baiba Šlisere 2BC , Anna Jana Saulīte 12EF , Ieva Ziediņa 14AB , Inese Folkmane 13AB , Harijs Čerņevskis 14DE , Juta Kroiča 2ACDF , Aivars Pētersons 14ACD , Viktorija Kuzema 14ACDEDOI: 10.12659/AOT.936751
Ann Transplant 2022; 27:e936751
Table 1 Baseline patient characteristics.
| Characteristic of patients | Value |
|---|---|
| Male, no. | 21 (60%) |
| Median patient age, years (Q1; Q3) | 57 (48; 64) |
| Primary diagnosis, no. | |
| Glomerulonephritis | 11 (31%) |
| Autosomal dominant polycystic kidney disease | 8 (23%) |
| Hypertensive nephropathy | 6 (17%) |
| Reflux nephropathy | 2 (6%) |
| Other | 8 (23%) |
| Donor, no. | |
| Living | 6 (17%) |
| Cadaveric | 29 (83%) |
| Kidney transplant, no. | |
| Primary | 29 (83%) |
| Re-transplant | 6 (17%) |
| Maintenance immunosuppression, no. | |
| Glucocorticoids | 24 (69%) |
| Tacrolimus | 26 (74%) |
| Cyclosporine | 5 (14%) |
| Mycophenolate mofetil | 34 (97%) |
| Sirolimus | 3 (9%) |
| Azathioprine | 1 (3%) |
| Kidney replacement therapy modality before transplantation, no. | |
| Hemodialysis | 21 (60%) |
| Peritoneal dialysis | 11 (31%) |
| Combined (hemodialysis and peritoneal dialysis) | 2 (6%) |
| Preemptive transplantation | 1 (3%) |